Redefining the future of NSCLC care: what do we still need to know

1
Chairs welcome and introduction
Nico van Zandwijk Sydney University,Asbestos
Diseases Research Institute,Sydney, Australia
2
Housekeeping

• Please turn off your mobilephones and pagers
• Questions please use the question cards or
  microphones provided

• Your feedback is valuable
• please complete theevaluation form

3
Meeting objectives

• Understand why inhibition of cellular pathways
  intrinsicto tumour growth/development is a
  rationaltherapeutic approach
• Examine clinical data for VEGF and EGFR pathway
  inhibitors
• Improve our understanding of how the mechanisms
  of action of anti-VEGF and anti-EGFR agents
  translate intoclinical efficacy
• Identify optimal patient management strategies
• Consider how we can further optimise patient
  outcomesin the future

EGFR epidermal growth factor receptor VEGF
vascular endothelial growth factor
4
Programme

• 12.30 Welcome and introduction Nico van
  Zandwijk (Australia)
• 12.35 Understanding the therapeutic potential of
  cellular signalling pathway inhibition Nico van
  Zandwijk (Australia)
• 12.45 Anti-VEGF therapy transforming patient
  outcomes in first-line NSCLC Martin Reck
  (Germany)
• 13.00 Delivering the promise of anti-EGFR therapy
  in advanced NSCLC Enriqueta Felip (Spain)
• 13.15 Delivering benefits from bench to bedside
  principles and guidance for optimal patient
  management Martin Reck (Germany)
• 13.35 QA session
• 13.50 Targeting NSCLC in the future Lucio Crinò
  (Italy)
• 14.00 Chairs close Nico van Zandwijk
  (Australia)

5
A wealth of molecular-targeted agents under
investigation in NSCLC
Angiogenesis inhibitors
EGFR/HER inhibitors
Phase II
Vatalanib
Lapatinib
Matuzumab
Sorafenib
Phase III
Sunitinib
Panitumumab
Cetuximab
Motesanib
Vandetanib
Tarceva
Neratinib
Avastin
Gefitinib
Cediranib
AS1404
Approved
Aflibercept
Talabostat
Bexarotene
CP-751871
Celecoxib
Bortezomib
Approved
Tipifarnib
ABT-751
First-lineSecond/third-line
AZD6244
Other molecular-targeted therapies
Everolimus
6
Redefining the future of NSCLC care what do we
still need to know?
Does simultaneous inhibition of the VEGF and
EGFR pathways further improve clinical outcomes?
Can we identify biomarkers that predict
clinical outcomes for anti-VEGF and anti-EGFR
therapy?
What is the efficacy/tolerability of
multi-targeted agents versus a combination of
specific drugs?